Baker Brothers portfolio, Q2 2025
Baker Bros. Advisors · 13F for the quarter ending Jun 30, 2025
For Q2 2025, Baker Bros. Advisors reported $10.3B across 89 US-listed positions, led by ONC (20.7%), INCY (20.3%) and ACAD (9.0%). Compared with its filing for Q1 2025, Baker Brothers opened 12 new positions, added to 23, reduced 8 and sold out of 12; 46 positions did not change.
The largest purchase was an addition to INSM ($234.7M); the largest sale, the sale of the whole position in Insmed Inc ($101.6M).
Key facts
- 13F portfolio value
- $10.3BQ2 2025
- Positions
- 89
- Largest holding
- ONC 20.7%
- New positions
- 12
- Sold out
- 12
- Filed
- Aug 14, 2025
Holdings as of (Q2 2025), filed with the SEC on . Changes are measured against the filing for Mar 31, 2025. Every tracked investor's Q2 2025 13F.
Bought and sold in Q2 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Insmed IncINSM | ▲ Added 43% | +2.33M | $234.7M | 2.28% |
| Summit Therapeutics IncSMMT | ▲ Added 38% | +9.3M | $197.9M | 1.92% |
Insmed Incno ticker on file | ▼ Sold out | — | $101.6M | 0.99% |
| Alkermes PLCALKS | ▲ Added 43% | +1.93M | $55.1M | 0.53% |
| Revolution Medicines IncRVMD | ▲ Added 18% | +1.43M | $52.5M | 0.51% |
| Structure Therapeutics IncGPCR | ▲ Added 594% | +2.15M | $44.5M | 0.43% |
| Ultragenyx PharmaceuticalRARE | ▲ Added 76% | +1.2M | $43.5M | 0.42% |
| BioNTech SEBNTX | ▲ Added 719% | +323.89K | $34.5M | 0.33% |
| Kymera Therapeutics IncKYMR | ▲ Added 11% | +655.5K | $28.6M | 0.28% |
| Viridian Therapeutics IncVRDN | ▲ New | +1.74M | $24.4M | 0.24% |
| CRISPR Therapeutics AGCRSP | ▼ Sold out | −654.1K | $22.3M | 0.22% |
| IDEAYA Biosciences IncIDYA | ▲ Added 99% | +1.06M | $22.2M | 0.22% |
| argenx SEARGX | ▼ Reduced 51% | −40K | $22M | 0.21% |
| Intellia Therapeutics IncNTLA | ▲ Added 315% | +2.03M | $19.1M | 0.18% |
Merus N Vno ticker on file | ▲ Added 157% | +350.88K | $18.5M | 0.18% |
Centessa Pharmaceuticals PLCno ticker on file | ▼ Sold out | −1.23M | $17.6M | 0.17% |
Blueprint Medicines Corpno ticker on file | ▲ New | +125.54K | $16.1M | 0.16% |
| Celcuity IncCELC | ▲ Added 28% | +1.19M | $15.9M | 0.15% |
| Immatics N.V.IMTX | ▲ Added 40% | +2.89M | $15.6M | 0.15% |
| Edgewise Therapeutics IncEWTX | ▲ Added 19% | +1.15M | $15.1M | 0.15% |
| Praxis Precision MedicinesPRAX | ▲ Added 108% | +357.96K | $15.1M | 0.15% |
| Arrowhead PharmaceuticalsARWR | ▲ New | +939.17K | $14.8M | 0.14% |
| Dianthus Therapeutics IncDNTH | ▲ New | +789.76K | $14.7M | 0.14% |
| Disc Medicine IncIRON | ▲ Added 337% | +260K | $13.8M | 0.13% |
2seventy bio Incno ticker on file | ▼ Sold out | −2.5M | $12.3M | 0.12% |
Akero Therapeutics Incno ticker on file | ▼ Reduced 41% | −224.08K | $12M | 0.12% |
Cidara Therapeutics Incno ticker on file | ▲ New | +227.27K | $11.1M | 0.11% |
Arcellx Incno ticker on file | ▲ New | +166.83K | $11M | 0.11% |
Nuvalent Incno ticker on file | ▲ New | +143.94K | $11M | 0.11% |
| Bicara Therapeutics IncBCAX | ▼ Sold out | −833.33K | $10.9M | 0.11% |
| Ionis Pharmaceuticals IncIONS | ▼ Sold out | −357.92K | $10.8M | 0.10% |
| Candel Therapeutics IncCADL | ▼ Reduced 85% | −2.08M | $10.5M | 0.10% |
| Spyre Therapeutics IncSYRE | ▲ New | +626.7K | $9.4M | 0.09% |
| Cerus CorpCERS | ▼ Reduced 33% | −6.47M | $9.1M | 0.09% |
| Celldex Therapeutics IncCLDX | ▲ Added 169% | +417.73K | $8.5M | 0.08% |
Crinetics Pharmaceuticalsno ticker on file | ▲ New | +280K | $8.1M | 0.08% |
| CytomX Therapeutics IncCTMX | ▲ New | +3.48M | $7.9M | 0.08% |
| Neurogene IncNGNE | ▼ Reduced 33% | −494.51K | $7.4M | 0.07% |
| Dyne Therapeutics IncDYN | ▼ Sold out | −672.1K | $7M | 0.07% |
| Agios Pharmaceuticals IncAGIO | ▲ New | +189.87K | $6.3M | 0.06% |
| Rapport Therapeutics IncRAPP | ▲ New | +550.09K | $6.3M | 0.06% |
Regulus Therapeutics Incno ticker on file | ▼ Sold out | −2.69M | $4.7M | 0.05% |
| Prime Medicine IncPRME | ▼ Sold out | −1.03M | $2M | 0.02% |
| Rocket Pharmaceuticals IncRCKT | ▼ Reduced 50% | −545K | $1.3M | 0.01% |
| Compass Therapeutics IncCMPX | ▼ Sold out | −547.5K | $1M | 0.01% |
| Fate Therapeutics IncFATE | ▼ Reduced 24% | −773.38K | $866.2K | 0.01% |
| Xenon Pharmaceuticals IncXENE | ▲ Added 6.6% | +22.8K | $713.6K | 0.01% |
| Madrigal Pharmaceuticals IncMDGL | ▲ Added 0.07% | +1.43K | $432.2K | 0.00% |
| Acadia Pharmaceuticals IncACAD | ▲ Added 0.04% | +18.77K | $405K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.01% | +3.32K | $226.2K | 0.00% |
| Kiniksa Pharmaceuticals InternationalKNSA | ▲ Added 0.2% | +6.35K | $175.6K | 0.00% |
Leap Therapeutics Incno ticker on file | ▼ Sold out | −404.74K | $123.5K | 0.00% |
| Century Therapeutics IncIPSC | ▼ Sold out | −241.68K | $115K | 0.00% |
| Design Therapeutics IncDSGN | ▼ Reduced 1.8% | −30.84K | $103.9K | 0.00% |
IGM Biosciences Incno ticker on file | ▲ Added 0.02% | +953 | $1.1K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 20.7% | $2.1B | 8.8M | $242.07 | 5+ qtrs | No change |
| 2 | Incyte CorpINCY | Health Care | 20.3% | $2.1B | 30.74M | $68.10 | 5+ qtrs | ▲ Added 0.01% |
| 3 | Acadia Pharmaceuticals IncACAD | — | 8.98% | $925.3M | 42.9M | $21.57 | 5+ qtrs | ▲ Added 0.04% |
| 4 | Insmed IncINSM | Health Care | 7.53% | $776.2M | 7.71M | $100.64 | 5+ qtrs | ▲ Added 43% |
| 5 | Summit Therapeutics IncSMMT | Health Care | 6.96% | $717.6M | 33.72M | $21.28 | 5+ qtrs | ▲ Added 38% |
| 6 | Madrigal Pharmaceuticals IncMDGL | Health Care | 5.80% | $598M | 1.98M | $302.64 | 5+ qtrs | ▲ Added 0.07% |
| 7 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.44% | $354.1M | 5.6M | $63.19 | 5+ qtrs | No change |
| 8 | Revolution Medicines IncRVMD | Health Care | 3.34% | $344.5M | 9.36M | $36.79 | 5+ qtrs | ▲ Added 18% |
| 9 | Kymera Therapeutics IncKYMR | Health Care | 2.82% | $290.3M | 6.65M | $43.64 | 5+ qtrs | ▲ Added 11% |
| 10 | Alkermes PLCALKS · SHS | Health Care | 1.78% | $183.4M | 6.41M | $28.61 | 5+ qtrs | ▲ Added 43% |
| 11 | Replimune Group IncREPL | — | 1.00% | $102.6M | 11.05M | $9.29 | 5+ qtrs | No change |
| 12 | Ultragenyx PharmaceuticalRARE | — | 0.98% | $100.8M | 2.77M | $36.36 | 5+ qtrs | ▲ Added 76% |
| 13 | Edgewise Therapeutics IncEWTX | Health Care | 0.93% | $95.8M | 7.31M | $13.11 | 5+ qtrs | ▲ Added 19% |
| 14 | Abcellera Biologics IncABCL | — | 0.92% | $94.4M | 27.53M | $3.43 | 5+ qtrs | No change |
| 15 | Immunovant IncIMVT | Health Care | 0.85% | $87.3M | 5.46M | $16.00 | 5+ qtrs | No change |
| 16 | Grail IncGRAL | Health Care | 0.81% | $83.8M | 1.63M | $51.42 | 3 qtrs | No change |
| 17 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.76% | $78.2M | 2.82M | $27.67 | 5+ qtrs | ▲ Added 0.2% |
| 18 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 0.73% | $75.7M | 10.89M | $6.95 | 5+ qtrs | No change |
| 19 | Immunocore Holdings plcIMCR · ADS | — | 0.71% | $72.9M | 2.32M | $31.38 | 5+ qtrs | No change |
| 20 | Celcuity IncCELC | — | 0.71% | $72.8M | 5.45M | $13.35 | 5+ qtrs | ▲ Added 28% |
| 21 | Kodiak Sciences IncKOD | Health Care | 0.63% | $64.6M | 17.31M | $3.73 | 5+ qtrs | No change |
| 22 | Immatics N.V.IMTX · SHS | — | 0.53% | $54.7M | 10.17M | $5.38 | 5+ qtrs | ▲ Added 40% |
| 23 | Stoke Therapeutics IncSTOK | — | 0.51% | $52.6M | 4.63M | $11.35 | 5+ qtrs | No change |
| 24 | Denali Therapeutics IncDNLI | — | 0.51% | $52.2M | 3.73M | $13.99 | 5+ qtrs | No change |
| 25 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.51% | $52M | 2.51M | $20.74 | 4 qtrs | ▲ Added 594% |
| 26 | IDEAYA Biosciences IncIDYA | — | 0.43% | $44.5M | 2.12M | $21.02 | 5+ qtrs | ▲ Added 99% |
| 27 | Nurix Therapeutics IncNRIX | — | 0.43% | $44.2M | 3.88M | $11.39 | 5+ qtrs | No change |
| 28 | Roivant Sciences LtdROIV · SHS | Health Care | 0.41% | $42.5M | 3.77M | $11.27 | 5+ qtrs | No change |
| 29 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.38% | $39.3M | 368.92K | $106.47 | 3 qtrs | ▲ Added 719% |
| 30 | Entrada Therapeutics IncTRDA | — | 0.32% | $32.7M | 4.87M | $6.72 | 5+ qtrs | No change |
| 31 | Merus N Vno ticker on file | — | 0.29% | $30.2M | 574.38K | $52.60 | 5+ qtrs | ▲ Added 157% |
| 32 | Praxis Precision MedicinesPRAX | Health Care | 0.28% | $29M | 689.49K | $42.05 | 5+ qtrs | ▲ Added 108% |
| 33 | Intellia Therapeutics IncNTLA | — | 0.24% | $25.1M | 2.68M | $9.38 | 3 qtrs | ▲ Added 315% |
| 34 | Viridian Therapeutics IncVRDN | — | 0.24% | $24.4M | 1.74M | $13.98 | 1 qtr | New |
| 35 | Monte Rosa Therapeutics IncGLUE | — | 0.22% | $22.2M | 4.92M | $4.51 | 5+ qtrs | No change |
| 36 | Verona Pharma Plcno ticker on file · SPONSORED ADS | — | 0.21% | $21.2M | 223.84K | $94.58 | 2 qtrs | No change |
| 37 | Vaxcyte IncPCVX | Health Care | 0.20% | $20.8M | 640.89K | $32.51 | 5+ qtrs | No change |
| 38 | argenx SEARGX · SPONSORED ADR | Health Care | 0.20% | $20.8M | 37.76K | $551.22 | 5+ qtrs | ▼ Reduced 51% |
| 39 | Verve Therapeutics Incno ticker on file | — | 0.18% | $19M | 1.69M | $11.23 | 5+ qtrs | No change |
| 40 | Cerus CorpCERS | — | 0.18% | $18.2M | 12.88M | $1.41 | 5+ qtrs | ▼ Reduced 33% |
| 41 | Disc Medicine IncIRON | — | 0.17% | $17.9M | 337.05K | $52.96 | 3 qtrs | ▲ Added 337% |
| 42 | Akero Therapeutics Incno ticker on file | — | 0.17% | $17.3M | 324.63K | $53.36 | 5+ qtrs | ▼ Reduced 41% |
| 43 | Blueprint Medicines Corpno ticker on file | — | 0.16% | $16.1M | 125.54K | $128.18 | 1 qtr | New |
| 44 | Sera Prognostics IncSERA · CLASS A COM | — | 0.15% | $15.2M | 5.5M | $2.77 | 5+ qtrs | No change |
| 45 | Arrowhead PharmaceuticalsARWR | Health Care | 0.14% | $14.8M | 939.17K | $15.80 | 1 qtr | New |
| 46 | Neurogene IncNGNE | — | 0.14% | $14.8M | 991.69K | $14.95 | 5+ qtrs | ▼ Reduced 33% |
| 47 | Dianthus Therapeutics IncDNTH | Health Care | 0.14% | $14.7M | 789.76K | $18.63 | 1 qtr | New |
| 48 | Celldex Therapeutics IncCLDX | — | 0.13% | $13.5M | 665.37K | $20.35 | 5+ qtrs | ▲ Added 169% |
| 49 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.13% | $13.4M | 1.46M | $9.16 | 5+ qtrs | No change |
| 50 | Xenon Pharmaceuticals IncXENE | — | 0.11% | $11.6M | 370.21K | $31.30 | 5+ qtrs | ▲ Added 6.6% |
| 51 | Cidara Therapeutics Incno ticker on file | — | 0.11% | $11.1M | 227.27K | $48.71 | 1 qtr | New |
| 52 | Arcellx Incno ticker on file | — | 0.11% | $11M | 166.83K | $65.85 | 1 qtr | New |
| 53 | Nuvalent Incno ticker on file | — | 0.11% | $11M | 143.94K | $76.30 | 1 qtr | New |
| 54 | Spyre Therapeutics IncSYRE | Health Care | 0.09% | $9.4M | 626.7K | $14.97 | 1 qtr | New |
| 55 | Taysha Gene Therapies IncTSHA | — | 0.09% | $9.3M | 4M | $2.31 | 5+ qtrs | No change |
| 56 | Prelude Therapeutics IncPRLD | — | 0.08% | $8.2M | 10.12M | $0.8094 | 5+ qtrs | No change |
| 57 | Crinetics Pharmaceuticalsno ticker on file | — | 0.08% | $8.1M | 280K | $28.76 | 1 qtr | New |
| 58 | CytomX Therapeutics IncCTMX | — | 0.08% | $7.9M | 3.48M | $2.27 | 1 qtr | New |
| 59 | Sagimet Biosciences IncSGMT | — | 0.07% | $7.3M | 953K | $7.62 | 5+ qtrs | No change |
| 60 | Sionna Therapeutics IncSION | — | 0.07% | $6.9M | 400K | $17.35 | 2 qtrs | No change |
| 61 | Agios Pharmaceuticals IncAGIO | — | 0.06% | $6.3M | 189.87K | $33.26 | 1 qtr | New |
| 62 | Rapport Therapeutics IncRAPP | — | 0.06% | $6.3M | 550.09K | $11.37 | 1 qtr | New |
| 63 | Skye Bioscience IncSKYE | — | 0.06% | $6.1M | 1.45M | $4.18 | 5+ qtrs | No change |
| 64 | Design Therapeutics IncDSGN | — | 0.06% | $5.8M | 1.71M | $3.37 | 5+ qtrs | ▼ Reduced 1.8% |
| 65 | KALA BIO IncKALA | — | 0.06% | $5.7M | 1.2M | $4.76 | 5+ qtrs | No change |
| 66 | Sana Biotechnology IncSANA | — | 0.05% | $5.5M | 2.03M | $2.73 | 5+ qtrs | No change |
| 67 | Xencor IncXNCR | — | 0.05% | $5.3M | 670.43K | $7.86 | 5+ qtrs | No change |
| 68 | Alumis IncALMS | — | 0.05% | $4.7M | 1.56M | $3.00 | 5+ qtrs | No change |
| 69 | IGM Biosciences Incno ticker on file | — | 0.05% | $4.6M | 4.1M | $1.12 | 5+ qtrs | ▲ Added 0.02% |
| 70 | TScan Therapeutics IncTCRX | — | 0.04% | $4M | 2.78M | $1.45 | 5+ qtrs | No change |
| 71 | Relay Therapeutics IncRLAY | — | 0.04% | $4M | 1.16M | $3.46 | 5+ qtrs | No change |
| 72 | Fate Therapeutics IncFATE | — | 0.03% | $2.8M | 2.49M | $1.12 | 5+ qtrs | ▼ Reduced 24% |
| 73 | Vir Biotechnology IncVIR | — | 0.03% | $2.7M | 542.54K | $5.04 | 3 qtrs | No change |
| 74 | Enliven Therapeutics IncELVN | — | 0.02% | $2.3M | 114.83K | $20.06 | 5+ qtrs | No change |
| 75 | Wave Life Sciences LtdWVE · SHS | — | 0.02% | $2.2M | 344.06K | $6.50 | 4 qtrs | No change |
| 76 | Tectonic Therapeutic IncTECX | — | 0.02% | $2M | 100K | $19.87 | 2 qtrs | No change |
| 77 | Candel Therapeutics IncCADL | — | 0.02% | $1.8M | 355.11K | $5.06 | 3 qtrs | ▼ Reduced 85% |
| 78 | Protara Therapeutics IncTARA | — | 0.02% | $1.6M | 536.83K | $3.03 | 5+ qtrs | No change |
| 79 | vTv Therapeutics IncVTVT · CL A | — | 0.01% | $1.5M | 97.31K | $15.00 | 5+ qtrs | No change |
| 80 | Rocket Pharmaceuticals IncRCKT | — | 0.01% | $1.4M | 552.08K | $2.45 | 3 qtrs | ▼ Reduced 50% |
| 81 | Contineum Therapeutics IncCTNM · CL A | — | 0.01% | $1.2M | 312.5K | $3.97 | 5+ qtrs | No change |
| 82 | HOOKIPA Pharma Incno ticker on file | — | 0.01% | $1M | 812.81K | $1.26 | 5+ qtrs | No change |
| 83 | Neumora Therapeutics IncNMRA | — | 0.01% | $758.7K | 1.03M | $0.7333 | 5+ qtrs | No change |
| 84 | Generation Bio Cono ticker on file | — | 0.01% | $622.6K | 1.94M | $0.3201 | 5+ qtrs | No change |
| 85 | Aligos Therapeutics IncALGS | — | 0.01% | $598.8K | 83.06K | $7.21 | 5+ qtrs | No change |
| 86 | Tyra Biosciences IncTYRA | — | 0.00% | $101.5K | 10.61K | $9.57 | 5+ qtrs | No change |
| 87 | Acrivon Therapeutics IncACRV | — | 0.00% | $27.1K | 22.81K | $1.19 | 5+ qtrs | No change |
| 88 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $15.1K | 833.33K | $0.0181 | 5+ qtrs | No change |
| 89 | Opthea Limitedno ticker on file · SPONSORED ADS | — | 0.00% | $0 | 2.09M | — | 5+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 78.5% | $8.1B | 22 |
| No sector on file | 21.5% | $2.2B | 67 |
Questions and answers
What did Baker Brothers own in Q2 2025?
Baker Bros. Advisors's 13F for Q2 2025 lists 89 positions worth $10.3B. The largest: ONC (20.7%), INCY (20.3%), ACAD (9.0%), INSM (7.5%), SMMT (7.0%).
What did Baker Brothers buy in Q2 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: INSM (added, $234.7M), SMMT (added, $197.9M), ALKS (added, $55.1M), RVMD (added, $52.5M), GPCR (added, $44.5M), RARE (added, $43.5M).
What did Baker Brothers sell in Q2 2025?
The largest sales: Insmed Inc (sold out, $101.6M), CRSP (sold out, $22.3M), ARGX (reduced, $22M), Centessa Pharmaceuticals PLC (sold out, $17.6M), 2seventy bio Inc (sold out, $12.3M), Akero Therapeutics Inc (reduced, $12M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Jun 30, 2025 on Aug 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q2 2025: Baker Bros. Advisors 13F holdings”, data as of 14 August 2025. https://funkfolio.com/gurus/baker-brothers/2025-q2
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Jun 30, 2025.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Jun 30, 2025, filed Aug 14, 2025. Changes compare share counts with the filing for Mar 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $10.3B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 5 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.